1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress)

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Park, H; Bekaii-Saab, T; Kim, S; Kamath, S; Pishvaian, M; Ford, J; Zhen, D; Mayor, J; Lux, C; Tan, Q; Strickler, J

Published Date

  • September 2021

Published In

Volume / Issue

  • 32 /

Start / End Page

  • S1073 - S1074

Published By

International Standard Serial Number (ISSN)

  • 0923-7534

Digital Object Identifier (DOI)

  • 10.1016/j.annonc.2021.08.1546